Aidoc Receives FDA Breakthrough Designation for AI Radiology Report Drafting
Aidoc has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its new AI tool called First Read, announced in a press release. The system analyzes chest radiographs and generates preliminary radiology report text to assist radiologists in managing rising imaging volumes.
First Read extends Aidoc's CARE foundation model into report drafting workflows. It is intended to reduce reporting time by producing high quality draft text from imaging findings, allowing radiologists to focus on interpretation and clinical decision making. The company states that the model builds on the same architecture as its FDA cleared abdominal CT triage application.
This is Aidoc’s second Breakthrough Device Designation within a year, following CARE Triage in September 2025. The designation is reserved for technologies that significantly advance diagnosis or treatment of serious conditions and address unmet clinical needs.
Aidoc’s platform, deployed across nearly 2,000 hospitals, integrates AI into imaging and electronic medical record systems through its aiOS operating system. The company reports that its technology has analyzed over 120 million patient cases worldwide.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation
The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.
Read more